Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 18.46M P/E - EPS this Y 83.00% Ern Qtrly Grth -
Income -12.59M Forward P/E -1.42 EPS next Y -40.00% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -17.00%
Dividend N/A Price/Book 0.84 EPS next 5Y - 52W High Chg -62.00%
Recommedations 1.70 Quick Ratio 4.89 Shares Outstanding 10.75M 52W Low Chg 1.00%
Insider Own 20.34% ROA -64.92% Shares Float 3.88M Beta -
Inst Own 54.29% ROE -83.76% Shares Shorted/Prior 24.78K/23.22K Price 3.26
Gross Margin - Profit Margin - Avg. Volume 28,300 Target Price 18.33
Oper. Margin - Earnings Date Nov 7 Volume 10,005 Change -0.91%
About CalciMedica, Inc.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

CalciMedica, Inc. News
08:00 AM CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/20/24 CalciMedica Announces Presentations at Upcoming Medical Meetings
11/13/24 CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
11/07/24 CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
10/30/24 CalciMedica Announces Pricing of Public Offering of Common Stock
10/30/24 CalciMedica Announces Proposed Public Offering of Common Stock
10/30/24 CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
10/28/24 CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
10/16/24 CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
09/03/24 CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/12/24 CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
07/09/24 CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)
07/08/24 CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences
07/01/24 CalciMedica Set to Join Russell Microcap® Index
06/27/24 CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
06/26/24 CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
05/13/24 CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
05/07/24 CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024
04/24/24 CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
03/28/24 CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
CALC Chatroom

User Image MrAlientrader Posted - 1 week ago

$CALC just let it sink, you will buy shares much cheaper than institutes and insiders

User Image MrAlientrader Posted - 1 week ago

$CALC they keep manipulating just to make sure the price closed a big lower everyday

User Image insiderbuyingselling Posted - 2 weeks ago

$CALC new insider buying: 3000 shares. http://insiderbuyingselling.com/?t=CALC

User Image MrAlientrader Posted - 2 weeks ago

$CALC institutes own 22.51% shares and insiders own 49.42 according to Fintel

User Image MrAlientrader Posted - 2 weeks ago

$XBI $CALC insiders buy crazy total over 320k shares bought just in Nov @$3.75 per share, 3 insiders are 10% owner. No insiders ever sold. However, someone unknown selling crazier and desperate want the price go lower

User Image insiderbuyingselling Posted - 2 weeks ago

$CALC new insider buying: 87744 shares. http://insiderbuyingselling.com/?t=CALC

User Image MrAlientrader Posted - 2 weeks ago

$CALC lowered my buy price around $3

User Image MrAlientrader Posted - 2 weeks ago

$CALC insiders buy like crazy, they always buy when it drops below $4z why they are so confident to put millions in this stock

User Image MrAlientrader Posted - 2 weeks ago

$CALC still have someone try to drive the price down using small number shares.

User Image CEOBuysDisclosures Posted - 2 weeks ago

$CALC CEO purchased 20,000 shares at $3.75 for a total of $75,000. Leheny A. Rachel now owns 871,252 shares. https://ceo-buys.com

User Image MrAlientrader Posted - 2 weeks ago

$CALC wow insiders have been buying the merger, no sell. and both CEO and CBO are now 10% owner. Insiders just bought over 120k shares yesterday. All institute holders are now underwater

User Image insiderbuyingselling Posted - 2 weeks ago

$CALC new insider buying: 20000 shares. http://insiderbuyingselling.com/?t=CALC

User Image EpiCRise98 Posted - 2 weeks ago

$CALC watching 👀

User Image EpiCRise98 Posted - 2 weeks ago

$CALC CalciMedica, Inc. (ticker: CALC) has disclosed a series of share acquisitions by senior executives and directors. On November 1, 2024, Rachel Leheny A., serving as the Chief Executive Officer and holding positions as a Director and a 10% Owner, purchased 20,000 shares of the company at a price of $3.75 per share. Concurrently, Eric W. Roberts, fulfilling the roles of Director, 10% Owner, and Chief Business Officer, acquired 53,333 shares at the same price point. Additionally, Director Robert N. Wilson also participated in the buying, securing 53,333 shares, each at $3.75.

User Image pablo4 Posted - 2 weeks ago

$CALC I've done great trading calc from the 3s to the 5s a couple of rounds. Now's the time to add again. The insiders bought some of this recent financing round at 3.75. Form 4s are coming out now. JMO

User Image insiderbuyingselling Posted - 2 weeks ago

$CALC new insider buying: 53333 shares. http://insiderbuyingselling.com/?t=CALC

User Image sh64 Posted - 2 weeks ago

$CALC 2025 should be a good year for this stock will wait another year

User Image OpenOutcrier Posted - 10/31/24

$CALC (-19.6% pre) CalciMedica Announces Pricing of Public Offering of Common Stock - SI https://ooc.bz/l/46504

User Image MrAlientrader Posted - 10/31/24

$CALC now we know why they always try to hold the price down in the last couple weeks/months, they want low price shares as the last offering in Jan was $3.7 per share private placement for existing shareholders.

User Image MrAlientrader Posted - 10/31/24

$CALC it is a quite good offering, no big discount and no warrant attached. Clear and straightforward which shows lots interest from the market

User Image MrAlientrader Posted - 10/31/24

$CALC the offering was same price as last time. It is good for a trial stage bio company. Everyone knew they need fund to proceed the trial further.

User Image CAD_CAM Posted - 10/31/24

$CALC CalciMedica recently made three back-to-back announcements to support its clinical programs: 1. Stock Offering: CalciMedica launched a public offering to raise approximately $10.2 million in gross proceeds for advancing its lead product, Auxora™, in inflammatory disease trials. 2. Additional Shares Option: Underwriters received an option to purchase an extra 408,000 shares, potentially increasing funds for clinical initiatives. 3. Book-Running Manager Appointment: JonesTrading Institutional Services LLC was appointed as the book-running manager, overseeing the offering and distribution. These moves aim to strengthen CalciMedica’s financial resources for its pipeline’s development.

User Image bandido20 Posted - 10/30/24

$JL chart looks sexy af. Today ended with around 17 million in volume, bit more than half of yesterday volume, but … we are in beter position than yesterday. More than 900k shares have been borrow and hourly chart imo is screaming for a squeeze. Last news were about 2 to 3 weeks ago. Maybe tomorrow we might get some update and will ingnite the squeeze as $TTI $CALC or $ASPI did Just have 👀

User Image realestateguy Posted - 10/30/24

$CALC they did an offering smh. Can’t win with this stock.

User Image MrAlientrader Posted - 10/30/24

$CALC what kind of idiot didn’t sell during the market time above $5 but choose to sell after close below $4?

User Image mgogel Posted - 10/30/24

$MAXN $CALC $VSTE $RDDT $GRI

User Image CAD_CAM Posted - 10/30/24

$CALC $DRUG $ENSC $TVGN $MNPR Exciting Progress at CalciMedica! 🌟 We’re advancing in the fight against acute pancreatitis and kidney injury with Auxora™, our breakthrough therapy. Just presented at the American College of Gastroenterology, Auxora’s latest results bring hope to patients and highlight the power of innovative biopharma. Stay tuned for our upcoming earnings on Nov 14th for more updates! 📈

User Image DjStockTrades Posted - 10/30/24

$CALC added. Good news here think this one being slept on. $ENSC $THAR

User Image Chrissytina Posted - 10/30/24

$CALC Nice pop but the question is Will it hold? 🤷🏼‍♀️

User Image MrAlientrader Posted - 10/30/24

$CALC more funds/buyers will see this name above $5. This stock has been holding down for a long time

Analyst Ratings
HC Wainwright & Co. Buy Aug 13, 24
Oppenheimer Outperform Jul 10, 24
HC Wainwright & Co. Buy Jul 9, 24
HC Wainwright & Co. Buy Jun 27, 24
HC Wainwright & Co. Buy May 14, 24
Oppenheimer Outperform Apr 1, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 13, 24
JonesTrading Buy Feb 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MIDDLETON FRED A Director Director Jan 23 Buy 3.7 679,384 2,513,721 30,292 01/25/24
Sanderling Venture Partners VI... Director Director Jan 23 Buy 3.7 679,384 2,513,721 30,292 01/25/24
WILSON ROBERT N Director Director Dec 11 Buy 3.30 506 1,670 182,161 12/13/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Nov 07 Buy 3.34 2,000 6,680 18,840 11/08/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Nov 06 Buy 3.12 2,400 7,488 35,894 11/08/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Nov 03 Buy 2.8 14,949 41,857 33,494 11/07/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Nov 06 Buy 3.1208 2,440 7,615 16,840 11/07/23
Hebbar Sudarshan Chief Medical Office.. Chief Medical Officer Nov 03 Buy 2.7389 36,000 98,600 46,000 11/07/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Aug 25 Buy 3.02 223 673 5,223 09/05/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Aug 21 Buy 3.26 2,464 8,033 4,264 08/23/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 23 Buy 3.53 1,900 6,707 13,387 06/26/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Jun 08 Buy 5.225 1,000 5,225 9,000 06/15/23
MIDDLETON FRED A Director Director Jun 09 Buy 5.20 714 3,713 11,714 06/09/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 08 Buy 5.20 485 2,522 13,185 06/09/23
MIDDLETON FRED A Director Director Jun 06 Buy 5.04 1,000 5,040 11,000 06/08/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 06 Buy 5.16 4,700 24,252 12,700 06/08/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Jun 06 Buy 5.19 2,000 10,380 8,000 06/08/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Jun 02 Buy 4.80 1,000 4,800 6,000 06/05/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer May 16 Buy 2.698 1,000 2,698 1,000 06/05/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 01 Buy 4.66 3,687 17,181 12,187 06/05/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer May 31 Buy 4.21 1,000 4,210 5,000 06/01/23
BJERKHOLT ERIC Director Director May 30 Buy 3.85 255 982 3,684 06/01/23
Roberts Eric W Chief Business Offic.. Chief Business Officer May 30 Buy 3.8616 2,000 7,723 8,000 06/01/23
BJERKHOLT ERIC Director Director May 23 Buy 3.268 500 1,634 3,429 05/24/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer May 23 Buy 3.3439 3,000 10,032 4,000 05/24/23
Roberts Eric W Chief Business Offic.. Chief Business Officer May 22 Buy 3.11 8,000 24,880 8,500 05/24/23
BJERKHOLT ERIC Director Director May 16 Buy 2.69 1,300 3,497 2,729 05/18/23
Hebbar Sudarshan Chief Medical Office.. Chief Medical Officer May 16 Buy 2.6999 10,000 26,999 10,000 05/18/23
Roberts Eric W Chief Business Offic.. Chief Business Officer May 16 Buy 2.7 8,300 22,410 1,800 05/18/23
BREUIL ROBERT S Chief Financial Offi.. Chief Financial Officer Mar 31 Sell 1.25 2,188 2,735 20,529 04/04/22